{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:56:35Z","timestamp":1755798995360,"version":"3.44.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijcha.2025.101711","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T19:33:41Z","timestamp":1748633621000},"page":"101711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anticoagulation use in rheumatic heart disease-associated atrial fibrillation: a study of real-world practice in Central Australia"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-6888","authenticated-orcid":false,"given":"Sonia","family":"Sawant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Terrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinmay","family":"Khandkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anosh","family":"Sivashanmugarajah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angus","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ijcha.2025.101711_b0005","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2018.06.063","article-title":"Rheumatic heart disease worldwide: JACC scientific expert panel","volume":"72","author":"Watkins","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6Part B","key":"10.1016\/j.ijcha.2025.101711_b0010","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.hroo.2022.09.020","article-title":"Management of atrial fibrillation in rheumatic heart disease","volume":"3","author":"Shenthar","year":"2022","journal-title":"Heart Rhythm O2"},{"key":"10.1016\/j.ijcha.2025.101711_b0015","unstructured":"Health AIo, Welfare. Acute rheumatic fever and rheumatic heart disease in Australia 2017-2021. Canberra: AIHW; 2023."},{"issue":"11","key":"10.1016\/j.ijcha.2025.101711_b0020","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ijcha.2025.101711_b0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcha.2025.101711_b0030","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcha.2025.101711_b0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5334\/gh.807","article-title":"Meta-analysis of the incidence, prevalence, and correlates of atrial fibrillation in rheumatic heart disease","volume":"15","author":"Noubiap","year":"2020","journal-title":"Glob. Heart"},{"issue":"4","key":"10.1016\/j.ijcha.2025.101711_b0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2025.101711_b0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjcard.2020.10.064","article-title":"Meta-analysis of safety and efficacy of direct oral anticoagulants versus warfarin according to time in therapeutic range in atrial fibrillation","volume":"140","author":"Lee","year":"2021","journal-title":"Am. J. Cardiol."},{"issue":"Supplement_1","key":"10.1016\/j.ijcha.2025.101711_b0050","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.0343","article-title":"Direct oral anticoagulants vs warfarin in non-valvular atrial fibrillation. Meta-analysis, includes all published trials","volume":"42","author":"Arreaga-Perez","year":"2021","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.ijcha.2025.101711_b0055","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.hlc.2019.11.006","article-title":"Quality of warfarin anticoagulation in indigenous and non-indigenous Australians with atrial fibrillation","volume":"29","author":"Nguyen","year":"2020","journal-title":"Heart Lung Circ."},{"issue":"12","key":"10.1016\/j.ijcha.2025.101711_b0060","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.hlc.2017.01.004","article-title":"Safety and efficacy of warfarin therapy in remote communities of the top end of Northern Australia","volume":"26","author":"Dennis","year":"2017","journal-title":"Heart Lung Circ."},{"issue":"10","key":"10.1016\/j.ijcha.2025.101711_b0065","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.hlc.2018.06.1043","article-title":"National heart foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical guidelines for the diagnosis and management of atrial fibrillation 2018","volume":"27","author":"Brieger","year":"2018","journal-title":"Heart Lung Circ."},{"issue":"19","key":"10.1016\/j.ijcha.2025.101711_b0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016851","article-title":"Contemporary incidence and prevalence of rheumatic fever and rheumatic heart disease in Australia using linked data: the case for policy change","volume":"9","author":"Katzenellenbogen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.ijcha.2025.101711_b0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ihj.2020.09.011","article-title":"Gender differences in the epidemiology of Rheumatic Fever\/Rheumatic heart disease (RF\/RHD) patient population of hill state of northern India; 9 years prospective hospital based, HP-RHD registry","volume":"72","author":"Negi","year":"2020","journal-title":"Indian Heart J."},{"issue":"8","key":"10.1016\/j.ijcha.2025.101711_b0080","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ijcha.2025.101711_b0085","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ijcha.2025.101711_b0090","doi-asserted-by":"crossref","first-page":"910","DOI":"10.7326\/M20-6194","article-title":"Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation","volume":"174","author":"Dawwas","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcha.2025.101711_b0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2022.03.037","article-title":"RIvaroxaban in mitral stenosis (RISE MS): a pilot randomized clinical trial","volume":"356","author":"Sadeghipour","year":"2022","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcha.2025.101711_b0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/hearts4030008","article-title":"Outcomes and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) amongst patients with valvular heart disease (VHD): a systematic review and meta-analysis","volume":"4","author":"Patel","year":"2023","journal-title":"Hearts"}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725001149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725001149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:04:11Z","timestamp":1755619451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906725001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"alternative-id":["S2352906725001149"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101711","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulation use in rheumatic heart disease-associated atrial fibrillation: a study of real-world practice in Central Australia","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101711"}}